Sol-Gel Technologies Ltd.: insider trades · United States · SEC (Form 4)

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd. is a U.S.-listed specialty biopharmaceutical company traded on the NASDAQ in the United States (United States), with a focused footprint in dermatology. The company was founded on October 28, 1997, and is headquartered in Ness Ziona, Israel, at Weizmann Science Park. Its core strategy is centered on developing and commercializing topical therapies for severe, rare, and high-unmet-need skin diseases, supported by a proprietary microencapsulation-based formulation platform designed to improve local delivery and tolerability of dermatologic actives. ([ir.sol-gel.com](https://ir.sol-gel.com/resources/investor-faqs?utm_source=openai)) Sol-Gel’s commercial history is anchored by two FDA-approved products: TWYNEO®, for acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY®, for inflammatory lesions of rosacea in adults. These approvals demonstrate the company’s ability to progress dermatology assets through clinical development and regulatory review. More recently, Sol-Gel has shifted increasing attention toward its proprietary pipeline, led by SGT-610, a topical patidegib gel currently in Phase 3 development for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. The pipeline also includes SGT-210, a topical erlotinib candidate being studied in Darier disease and other rare keratinization disorders. ([ir.sol-gel.com](https://ir.sol-gel.com/node/8896?utm_source=openai)) From a competitive standpoint, Sol-Gel remains a niche player relative to large global dermatology and specialty-pharma groups, but it has carved out a differentiated profile through focused topical formulation expertise, demonstrated regulatory execution, and a partnership-driven commercialization model outside the United States. The company has signed multiple ex-U.S. licensing agreements for TWYNEO and EPSOLAY, including arrangements in Europe, South Africa, Australia, and New Zealand, which broaden geographic reach while reducing the need for a large internal sales infrastructure. ([ir.sol-gel.com](https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-announces-signing-six-exclusive-license-agreements?utm_source=openai)) A key recent development was the April 2025 sale of the U.S. rights to EPSOLAY and TWYNEO to Mayne Pharma, following the mutual termination of Sol-Gel’s exclusive U.S. license agreement with Galderma. That transaction materially reshaped the company’s U.S. commercial exposure and made the clinical pipeline, especially SGT-610, even more central to the investment case. In March 2026, Sol-Gel also completed a new underwritten offering, underscoring that liquidity management and capital access remain important priorities as the company continues to fund clinical development and prepare for potential future commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1684693/000117891325002946/exhibit_99-1.htm?utm_source=openai))